Procept
Executive Summary
Has completed new round of venture capital financing totaling $ 9.25 mil., Cambridge, Mass.-based start-up said Aug. 22. Investors include Bristol-Myers Squibb. Procept is developing receptor-based therapeutics for immune system diseases, with a focus on AIDS, autoimmune disease, organ transplant rejection and allergy.